Cdk8 Antibody [G17E8] | Primary Antibodies

Application: Reactivity: Human

Usage Information

Dilution
WB1:1000 IP1:30

Application
WB, IP

Reactivity
Human

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
53 kDa 53 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight. Post-translational modifications(e.g., phosphorylation, glycosylation); Splice variants and isoforms; Relative charge; Multimerization.

Datasheet & SDS

Biological Description

Specificity
Cdk8 Antibody [G17E8] detects endogenous levels of total Cdk8 protein.

Clone
G17E8

Synonym(s)
Cyclin-dependent kinase 8, Cell division protein kinase 8, Mediator complex subunit CDK8, Mediator of RNA polymerase II transcription subunit CDK8, Protein kinase K35, CDK8

Background
CDK8 is a cyclin‑dependent kinase that functions as the catalytic core of the CDK8 kinase module within specific Mediator complexes and acts as a transcription‑regulatory kinase that integrates signaling inputs into RNA polymerase II–dependent gene expression programs. The kinase associates with cyclin C, MED12, and MED13 to form the CDK8 subcomplex, which binds the Mediator core in a reversible manner, and this configuration positions the CDK8 active site to phosphorylate components of the basal transcription machinery, transcription factors, and elongation regulators without being required for Mediator assembly itself. CDK8 phosphorylates transcription factors and coactivators, including members of the serum response and early growth response networks, and also targets the carboxy‑terminal domain of RNA polymerase II and elongation‑associated factors, which modulate the transition from initiation to productive elongation and the assembly and activity of the positive transcription elongation factor b–containing elongation complex. Within the serum response network, CDK8 acts as a positive regulator of transcriptional elongation by facilitating recruitment of P‑TEFb and BRD4 to promoters and enhancers and by preventing accumulation of hypophosphorylated, slow‑elongating RNA polymerase II complexes, which results in efficient induction of immediate‑early genes such as AP‑1 and EGR family transcription factors after mitogenic stimulation. The CDK8 kinase module also exerts context‑dependent repressive functions; Mediator complexes containing the CDK8 subcomplex can block preinitiation complex formation at some promoters and modulate the interaction between Mediator and RNA polymerase II, thereby controlling access of the basal machinery to specific transcription factor–bound regulatory regions. CDK8 activity participates in multiple signaling pathways, including Wnt/β‑catenin, TGF‑β/Smad, STAT, and nuclear hormone receptor pathways, by phosphorylating pathway‑specific transcription factors and co‑regulators and by adjusting the amplitude and duration of their transcriptional outputs, which link extracellular cues and oncogenic signaling to Mediator‑dependent gene expression. The CDK8 kinase module regulates sets of genes involved in metabolism, cell‑cycle progression, and survival, and acts as a node in life‑and‑death decisions through transcriptional control of apoptotic and autophagy genes and non‑transcriptional roles of cyclin C in mitochondrial dynamics.

Background

CDK8 is a cyclin‑dependent kinase that functions as the catalytic core of the CDK8 kinase module within specific Mediator complexes and acts as a transcription‑regulatory kinase that integrates signaling inputs into RNA polymerase II–dependent gene expression programs. The kinase associates with cyclin C, MED12, and MED13 to form the CDK8 subcomplex, which binds the Mediator core in a reversible manner, and this configuration positions the CDK8 active site to phosphorylate components of the basal transcription machinery, transcription factors, and elongation regulators without being required for Mediator assembly itself. CDK8 phosphorylates transcription factors and coactivators, including members of the serum response and early growth response networks, and also targets the carboxy‑terminal domain of RNA polymerase II and elongation‑associated factors, which modulate the transition from initiation to productive elongation and the assembly and activity of the positive transcription elongation factor b–containing elongation complex. Within the serum response network, CDK8 acts as a positive regulator of transcriptional elongation by facilitating recruitment of P‑TEFb and BRD4 to promoters and enhancers and by preventing accumulation of hypophosphorylated, slow‑elongating RNA polymerase II complexes, which results in efficient induction of immediate‑early genes such as AP‑1 and EGR family transcription factors after mitogenic stimulation. The CDK8 kinase module also exerts context‑dependent repressive functions; Mediator complexes containing the CDK8 subcomplex can block preinitiation complex formation at some promoters and modulate the interaction between Mediator and RNA polymerase II, thereby controlling access of the basal machinery to specific transcription factor–bound regulatory regions. CDK8 activity participates in multiple signaling pathways, including Wnt/β‑catenin, TGF‑β/Smad, STAT, and nuclear hormone receptor pathways, by phosphorylating pathway‑specific transcription factors and co‑regulators and by adjusting the amplitude and duration of their transcriptional outputs, which link extracellular cues and oncogenic signaling to Mediator‑dependent gene expression. The CDK8 kinase module regulates sets of genes involved in metabolism, cell‑cycle progression, and survival, and acts as a node in life‑and‑death decisions through transcriptional control of apoptotic and autophagy genes and non‑transcriptional roles of cyclin C in mitochondrial dynamics.

References
https://pubmed.ncbi.nlm.nih.gov/21327159/ https://pubmed.ncbi.nlm.nih.gov/19240132/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%